Akèy › Limfom Difize Gwo Selil B › North Dakota
Etid klinik pou Limfom Difize Gwo Selil B nan North Dakota
4 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan North Dakota.
Vil nan North Dakota
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Essentia Health Cancer Center-South University Clinic, Fargo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Sanford Health Roger Maris Cancer Center ( Site 0189), Fargo
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.